Omeros (OMER) to Release Earnings on Monday

Omeros (NASDAQ:OMER) will likely be announcing its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Omeros (NASDAQ:OMER) last issued its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.08. During the same quarter last year, the business posted ($0.15) earnings per share. On average, analysts expect Omeros to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Omeros Trading Down 4.1 %

Shares of OMER opened at $7.06 on Friday. The firm has a market cap of $409.93 million, a price-to-earnings ratio of -3.06 and a beta of 2.35. The stock has a 50 day moving average of $8.56 and a 200-day moving average of $7.65. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60.

Analyst Ratings Changes

OMER has been the topic of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, April 1st. Finally, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.